BR
Barinthus Biotherapeutics plc
BRNS · NASDAQ
$0.74 +5.99% (+$0.04)
1M +22.72%
Market Cap $30.2M
P/E Ratio -
Div. Yield -
ROE 59.18%
Bulios Fair Price
$0.51
31.1% downside
Current Price
$0.74
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BRNS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 0.53x
PEG N/A
P/E N/A
Growth
0 /100
Declining Book val. growth 32.65%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 50.97%
ROIC 61.15%
Asset turnover 0.00x
Debt
69 /100
Low Int. coverage -796.09x
Debt/Equity 0.18x
Current ratio 5.54x
Stability
13 /100
Unstable EPS volatility 849.26%
Beta -0.36x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BRNS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
William James Enright
Employees
14
Headquarters
Germantown
Upcoming events
06 NOV
Earnings
Upcoming earnings report